Corcept reports positive Phase 2 BELLA data for lifyorli in ovarian cancer

Corcept Therapeutics reported positive Part A results from its Phase 2 BELLA trial of lifyorli combined with nab-paclitaxel and bevacizumab in 95 women with recurrent, platinum-resistant ovarian cancer, showing a median progression-free survival of 7.2 months, an objective response rate of 59%, and 88% of patients alive at the six-month overall survival timepoint.

Detected & updated continuously · Source: Nebula